Influences of silicates and carnitine‐silicate mixtures on the inhibition of aggregation of erythrocytes elicited by the presence of fibrinogen
- 1 October 1995
- journal article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 165 (1) , 145-154
- https://doi.org/10.1002/jcp.1041650117
Abstract
Carnitine and acylcarnitine derivatives have been reported to inhibit cell aggregation (Fritz and Burdzy, 1989, J. Cell. Physiol., 140:18–28). A follow‐up of these observations showed that whereas the previously described effects of long‐chain acylcarnitines were well replicated, those of carnitine on erythrocytes showed marked variability. The latter phenomenon was traced to the presence of silicates in carnitine solutions derived from the use of sodium hydroxide solutions stored in glass containers for the neutralization of carnitine. The present experiments have led to the discovery that oligomeric forms of silicates are powerful inhibitors of red blood cell aggregation which otherwise occurs in the presence of fibrinogen alone. The active form(s) of silicates in this assay, which appear to be generated by polymerization of silicates in metasilicate solutions on neutralization, are unstable and therefore transient under usual conditions. We estimate that the active oligomeric forms contain between 4 to 18 silicon atoms per molecule. When maintained at ‐ 18°C in the presence of carnitine, but not in its absence, the active forms of oligomeric silicates remained stable for months, judging from their ability to inhibit cell aggregation. We conclude that carnitine stabilized the oligomeric form(s) of silicate, or that the species stabilized is an oligomeric silicate‐carnitine complex. Comparable concentrations of choline, deoxycarnitine, or γ‐aminobutyrate were less effective in stabilizing the active silicate oligomers. The active forms of the silicate oligomers had K'i values of about 10 μM, calculated as the monomeric form, in inhibiting red blood cell aggregation. The data indicate that free carnitine does not directly inhibit erythrocyte inhibition, as previously interpreted, whereas long‐chain acylcarnitine derivatives are active in the absence of silicates. Possible mechanism of actions of silicate oligomers on membranes are discussed. © 1995 Wiley‐Liss Inc.Keywords
This publication has 14 references indexed in Scilit:
- Index of ContributersPublished by Wiley ,2007
- Sites of action of carnitine and its derivatives on the cardiovascular system: interactions with membranesTrends in Pharmacological Sciences, 1993
- Coacervation in aqueous solutions of short chain tetraalkylammonium bromide and sodium silicateLangmuir, 1993
- Clusterin: Insights into a multifunctional proteinTrends in Endocrinology & Metabolism, 1993
- Inhibition of cell-cell adhesion and morphogenesis ofDictyostelium by carnitineJournal of Cellular Physiology, 1992
- Clustering of erythrocytes by fibrinogen is inhibited by carnitine: Evidence that sulfhydryl groups on red blood cell membranes are involved in carnitine actionsJournal of Cellular Physiology, 1991
- Novel action of carnitine: Inhibition of aggregation of dispersed cells elicited by clusterin in vitroJournal of Cellular Physiology, 1989
- Effect of colloidal silicic acid on lecithin bilayersBiochimica et Biophysica Acta (BBA) - Biomembranes, 1973
- Effects of Silicate Polymers on Erythrocytes in Presence and Absence of ComplementThe Journal of general physiology, 1962
- The Reaction of Low Molecular Weight Silicic Acids with Molybdic AcidJournal of the American Chemical Society, 1953